Background Rhabdomyolysis is a syndrome caused by the death of muscle tissue, which leads to the release of the muscle protein myoglobin into the circulation. The severity of rhabdomyolysis varies widely from asymptomatic to life threatening, and has many possible causes, including a specific classification associated with medications. This report suggests the potential for rhabdomyolysis induction by an interaction between ginkgo (Ginkgo biloba) and cannabis, in addition to recent strenuous exercise. Prompt identification of the aetiology and treatment are crucial in preventing complications and mortality. Clinical details A 26‐year‐old African American female presented to the emergency department (ED) with a chief complaint of worsening muscle pain and weakness, 2 days after exercise without adequate hydration. The patient reported recently starting a ginkgo supplement, in addition to her regular medications and confirmed marijuana use. Urinalysis and creatine kinase (CK) data collected in the ED were suggestive of rhabdomyolysis. Outcomes The patient was admitted to hospital. After rehydration with intravenous normal saline, her CK levels and symptoms improved. Conclusion Ginkgo is an increasingly popular natural supplement with a variety of uses. However, the use of this product, with or without cannabis consumption, may correspond to an increased likelihood for interactions and adverse drug reactions, such as the potential for rhabdomyolysis presented here. It is important for pharmacists and other clinicians to be aware of the prospective risks associated with this supplement in order to properly educate patients and mitigate potential morbidities.
Background Inhaled corticosteroid (ICS) therapy in patients with chronic obstructive pulmonary disease (COPD) has been associated with a variety of unfavourable effects, including increased risk of pneumonia, and is only recommended if specific characteristics are present to ensure patients derive the most benefit. Aim The primary objective was to evaluate the clinical characteristics of patients prescribed ICS therapy for COPD management in two primary care clinics at an academic medical centre. The secondary objectives were to examine provider assessment and barriers to prescribing patterns concordant with guidelines in the ambulatory care setting. Method A retrospective 24‐month study at two primary care clinics was undertaken at an academic medical centre in Arkansas, United States and focused on adult patients who were prescribed ICS maintenance therapy. Individuals within each clinic were identified by Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) codes indicative of COPD from 1 January 2019 to 31 December 2020. Spirometry was also required to confirm diagnosis. Results Of the 189 unique patients identified, 100 were eligible for review of clinical characteristics. All patients received ICS therapy in combination with a long‐acting beta agonist (LABA) with 55% of patients also receiving a long‐acting muscarinic antagonist (LAMA). Furthermore, 32% of patients visited the emergency department or were hospitalised for a COPD exacerbation within the previous year. Approximately 47% and 36% of patients had a history of pneumonia and an eosinophil count <100 cells/mcL respectively. Barriers to guideline adherence were identified through open discussion with providers within each clinic, which included a lack of readily available resources in the clinic setting, suboptimal recognition of clinical tools within the electronic medical record and alternative guideline preferences. Conclusion A small portion of patients evaluated in the study were discovered to have clinical characteristics suggestive of strong ICS benefit as these therapies either lacked efficacy due to low blood eosinophil count or exacerbation rate (80% and 68% respectively), or increased the risk for harm in this population secondary to previous pneumonia diagnosis (47%).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.